ReviewEBioMedicine2022
Current sepsis therapeutics.
Review in EBioMedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
125 citing papers in PubMed, 2 syntheses or guidelines pooled it, 168 citations in OpenAlex.
- The impact of traditional Chinese medicine on gastrointestinal dysfunction in sepsis patients: a systematic review and network meta-analysis.Frontiers in pharmacology · 2025Pooled it
- A meta-analysis of the association between vasopressor use and intensive care unit-acquired weakness.Brain and behavior · 2024Pooled it
- Exploring the mechanism of polymorphonuclear neutrophils against sepsis based on immune model.Annals of medicine · 2026Review
- Engineering a multifunctional nanoplatform with cascade catalytic and bidirectional immunomodulatory capacities for integrating sepsis therapy.Journal of advanced research · 2026Article
- Reverse-Engineered Lipid Nanoparticles Harness Protein Corona Formation for Cytokine Sequestration and Combination Immunomodulatory Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- RUNX3: a regulator of macrophage apoptosis with positive prognostic impact in sepsis.Genes & genomics · 2026Article
- Beyond Biomimetics: Pathology-Informed Engineering Rescues Reconstituted HDL From Inflammatory Dysfunction for Sepsis Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Associations of Heart Rate Trajectories with Mortality and AKI Occurrence in Septic Patients: A Retrospective Study from MIMIC-IV and eICU Databases.Journal of clinical medicine · 2026Article
- Macrophage PARP7 Alleviates Septic Cardiomyopathy by Interacting With TBK1 and Suppressing TBK1-Driven Inflammatory Response.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Epigenetic regulation of neutrophil dysfunction in sepsis: mechanisms, biomarkers, and translational challenges.Journal of translational medicine · 2026Review
- IL10 promotes surgical incision healing in sepsis by regulating PI16Clinical and experimental medicine · 2026Article
- The FDA-approved excipient N,N-dimethylacetamide improves survival and attenuates inflammatory pathways in a murine model of endotoxemia.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026Article
- Dexmedetomidine versus usual care in adult patients with septic shock receiving vasopressors: A systematic review and meta-analysis of randomised controlled trials.European journal of anaesthesiology and intensive care · 2026Review
- Sulfated bile acid produced by a human gut commensal alleviates paediatric sepsis in mice.Nature microbiology · 2026Article
- Identification and validation of MYC as an autophagy-related gene for diagnosis and immune infiltration in sepsis-induced myocardial dysfunction.Journal of cardiothoracic surgery · 2026Article
- Novel genetic insights into causal effects of potential metformin targets and immune mediation on sepsis.Biology direct · 2026Article
- CSTA and DDX24: potential biomarkers regulating ferroptosis in sepsis and their diagnostic value.BMC medical genomics · 2026Article
- Pharmacological Targeting of CXCR4 Attenuates Sepsis-Induced Intestinal Injury by Suppressing NLRP3/GSDMD-Mediated Pyroptosis.Inflammation · 2026Article
- Da Yuan Yin Regulates Gut Microbiota and Improves Intestinal Injury in Sepsis.Food science & nutrition · 2026Article
- A glycopeptide hydrogel confers protection and treatment in sepsis via recruitment and training of macrophages.Materials today. Bio · 2026Article
65 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of the patient with sepsis comprises three key branches: control of the underlying infection, haemodynamic stabilization, and modulation of the host response. Each aspect should be considered in all patients and, when relevant, managed at the same time. Infection control is applicable to all patients with sepsis and will include antibiotic therapy and often surgical intervention to remove an infectious source. Haemodynamic support involves fluid administration in all patients and vasoactive agents in patients with associated circulatory shock. Noradrenaline is the first choice vasopressor agent; inotropic agents, usually dobutamine, may be added in case of myocardial depression. No interventions directed at individual components of the host response to sepsis have yet been shown to improve outcomes, but glucocorticoids and vasopressin have a global impact on the response and can thus be considered in this category. A move toward more personalized treatment is needed across all three arms of sepsis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.